Sterling Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Sterling Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-106	Closed	-$322	–	3244
2024 Q4	$322	Hold	106	–	–	﹤0.01%	3078
2024 Q3	$550	Buy	+106	New	+$527	﹤0.01%	2824

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sterling Capital Management's RVNC Position: Q1 2025 in Review

Sterling Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 106 shares — an estimated $322 sold.

Sterling Capital Management first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $550 in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Sterling Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Sterling Capital Management sold 106 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $322.
Sterling Capital Management first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
Sterling Capital Management's Revance Therapeutics, Inc. position peaked at $550 in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Sterling Capital Management's 13F filing for Q1 2025, filed 13 May 2025.